Skip to main
GH
GH logo

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is experiencing strong growth, evidenced by a robust two-year revenue CAGR of 28% expected from 2023 to 2025, driven by anticipated strength in various cancer indications, new monitoring applications, and ongoing product enhancements. The company has demonstrated an optimistic outlook by increasing its annual revenue guidance for the Shield test and projecting a 31% year-over-year growth for 2025. Additionally, Guardant Health's share price has surged, reflecting a substantial market cap approaching $10 billion, which underscores its potential appeal to large fund managers amid increasing demand for its innovative oncology testing solutions.

Bears say

Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, which raises concerns about its growth trajectory. The company's adjusted EBITDA loss of $45.5 million in the third quarter of 2025 underscores ongoing financial challenges that could be exacerbated by potential regulatory setbacks or reimbursement issues. Furthermore, the anticipated reliance on research and development efficiencies, coupled with the need for compelling data, suggests that any negatives in product launches or financial outcomes could significantly impact investor sentiment and stock performance.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.